EAU 2020 Bladder Cancer
Viewing 1-15 of 15 articles
EAU 2020: Frailty and Cognitive Assessment in Patients Diagnosed with Muscle-Invasive Bladder Cancer
EAU 2020: Five Things I Wish I Would Have Known Earlier in My Career: Lessons from the Mentors - Bladder Cancer
EAU 2020: Perioperative Therapy for Urothelial Cancer: Should We Sequence All Urothelial Cancer Patients?
EAU 2020: Urinary Markers in Low-Grade Non-Muscle Invasive Bladder Cancer: Ready to Stop Cystoscopies
EAU 2020: Perioperative Therapy for Urothelial Cancer: PD-1/PD-L1 Inhibitors are Replacing Perioperative Chemotherapy
EAU 2020: Recurrence Risk in Patients with High Grade Non-Muscle Invasive Bladder Carcinoma in the Randomised Phase III Clinical Trial ‘NIMBUS’ Stratified for EORTC and CUETO Risk Categories. A contemporary Trend to Less Recurrences?
EAU 2020: Results from the phase III study of Nadofaregene Firadenovec: Safety and Efficacy in Patients with High-grade, BCG-unresponsive Non-Muscle Invasive Bladder Cancer